New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
07:15 EDTNBS, PSTI, CUR, OSIR, BCLI, ATHXRRY Publications to host a summit
8th Annual New York Stem Cell Summit '13 is being held in New York on February 19.
News For OSIR;PSTI;ATHX;CUR;NBS;BCLI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 7, 2015
09:38 EDTBCLIBrainStorm announces treatment of final patient in U.S. phase 2 ALS trial
Subscribe for More Information
07:34 EDTPSTIAlliance for Regenerative Medicine to hold a meeting
Stem Cell Meeting on the Mesa is being held in La Jolla, California on October 7-9.
October 6, 2015
08:05 EDTOSIROsiris announces initiation of Phase III trial for OTI-15-01
Subscribe for More Information
October 1, 2015
06:09 EDTOSIROsiris assumed with a Hold from Buy at Brean Capital
Brean Capital analyst Jason Wittes downgraded Osiris Therapeutics (OSIR) to Hold after assuming coverage of the name. The analyst views the stock as fairly valued at current levels and sees increased competition from Integra LifeSciences' (IART) entry into the diabetic foot ulcer market.
September 29, 2015
08:09 EDTCURNeuralstem reports good tolerance in NSI-566 trial in ALS
Neuralstem announced that nine-month Phase II and combined Phase I and Phase II data on the NSI-566 trial in amyotrophic lateral sclerosis, or ALS, was presented at the American Neurological Association Annual Meeting. The data showed that the intraspinal transplantation of the cells was safe and well-tolerated throughout the escalating doses, reaching a maximum tolerated dose of 16 million cells via 20 bilateral injections. There appeared to be no acceleration in disease progression due to the therapeutic intervention. Researchers calculated a 95% confidence limit around the slopes of decline of ALSFRSr scores, forced vital capacity and grip strength of the ProAct historical database subjects, and evaluated if trial subjects fell within or outside those limits.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use